The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

The closely watched chronic spontaneous urticaria (CSU, or hives) space chalked more early stage KIT inhibitor data as Third Harmonic Bio Inc. rolled out results from the phase I single and multiple ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...

Hives, also known as urticaria, are raised, itchy welts on your skin that occur due to an allergen. The reaction is ...

Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

Blueprint Medicines Corporation BPMC reported fourth-quarter 2024 adjusted loss of 79 cents per share, wider than the Zacks ...

Incyte says 2025 is expected to be a year of defining catalysts with four launches, four pivotal study readouts, at least ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).